|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
2.74/0.06
|
企業價值
2.42B
|
資產負債 |
每股賬面淨值
8.93
|
現金流量 |
現金流量率
0.09
|
損益表 |
收益
60.00M
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/25 00:36 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Itspipeline products include Rusfertide (PTG-300) and JNJ-2113. |